These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Precision medicine for psychopharmacology: a general introduction. Shin C; Han C; Pae CU; Patkar AA Expert Rev Neurother; 2016 Jul; 16(7):831-9. PubMed ID: 27104961 [TBL] [Abstract][Full Text] [Related]
6. Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Kantae V; Krekels EHJ; Esdonk MJV; Lindenburg P; Harms AC; Knibbe CAJ; Van der Graaf PH; Hankemeier T Metabolomics; 2017; 13(1):9. PubMed ID: 28058041 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacometabonomics - the novel way to personalized drug therapy]. Maslov DL; Balashova EE; Lokhov PG; Archakov AI Biomed Khim; 2017 Mar; 63(2):115-123. PubMed ID: 28414282 [TBL] [Abstract][Full Text] [Related]
9. From Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized Medicine. Everett JR Front Pharmacol; 2016; 7():297. PubMed ID: 27660611 [TBL] [Abstract][Full Text] [Related]
11. Metabolomics in pharmacology - a delve into the novel field of pharmacometabolomics. Mussap M; Loddo C; Fanni C; Fanos V Expert Rev Clin Pharmacol; 2020 Feb; 13(2):115-134. PubMed ID: 31958027 [No Abstract] [Full Text] [Related]
12. Pharmacometabonomics in humans: a new tool for personalized medicine. Everett JR Pharmacogenomics; 2015; 16(7):737-54. PubMed ID: 25929853 [TBL] [Abstract][Full Text] [Related]
13. Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization. Trifonova OP; Maslov DL; Balashova EE; Urazgildeeva GR; Abaimov DA; Fedotova EY; Poleschuk VV; Illarioshkin SN; Lokhov PG Diagnostics (Basel); 2020 May; 10(5):. PubMed ID: 32466249 [TBL] [Abstract][Full Text] [Related]
14. Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. Corona G; Rizzolio F; Giordano A; Toffoli G J Cell Physiol; 2012 Jul; 227(7):2827-31. PubMed ID: 22105661 [TBL] [Abstract][Full Text] [Related]
15. Metabolomics as a tool for personalizing medicine: 2012 update. Sun J; Beger RD; Schnackenberg LK Per Med; 2013 Mar; 10(2):149-161. PubMed ID: 29758850 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics. Aboel Dahab A; El-Hag D; Moutamed GM; Aboel Dahab S; Abuknesha R; Smith NW Cancer Chemother Pharmacol; 2016 Sep; 78(3):465-89. PubMed ID: 27061417 [TBL] [Abstract][Full Text] [Related]
17. Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity. Oh J; Yi S; Gu N; Shin D; Yu KS; Yoon SH; Cho JY; Jang IJ Genomics Inform; 2018 Sep; 16(3):52-58. PubMed ID: 30309203 [TBL] [Abstract][Full Text] [Related]
18. He C; Liu Y; Wang Y; Tang J; Tan Z; Li X; Chen Y; Huang Y; Chen X; Ouyang D; Zhou H; Peng J J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Sep; 1095():15-23. PubMed ID: 30041085 [TBL] [Abstract][Full Text] [Related]
19. Pharmacometabonomics: The Prediction of Drug Effects Using Metabolic Profiling. Everett JR Handb Exp Pharmacol; 2019; 260():263-299. PubMed ID: 31823071 [TBL] [Abstract][Full Text] [Related]